Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 16 | 2025 | 463 | 3.120 |
Why?
|
| Vascular Diseases | 2 | 2025 | 150 | 0.970 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 4 | 2024 | 426 | 0.950 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2024 | 211 | 0.910 |
Why?
|
| Lung Diseases | 2 | 2025 | 408 | 0.860 |
Why?
|
| Consensus | 1 | 2024 | 658 | 0.700 |
Why?
|
| Lung | 4 | 2025 | 1556 | 0.690 |
Why?
|
| Actigraphy | 2 | 2024 | 48 | 0.420 |
Why?
|
| Walk Test | 3 | 2025 | 28 | 0.330 |
Why?
|
| Infant, Newborn | 10 | 2025 | 8548 | 0.310 |
Why?
|
| Hemodynamics | 3 | 2022 | 861 | 0.300 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 463 | 0.250 |
Why?
|
| Portal System | 1 | 2025 | 36 | 0.230 |
Why?
|
| Child, Preschool | 10 | 2025 | 14736 | 0.230 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 18 | 0.230 |
Why?
|
| Exercise Tolerance | 1 | 2025 | 87 | 0.220 |
Why?
|
| Infant | 8 | 2024 | 13049 | 0.220 |
Why?
|
| Vascular Malformations | 1 | 2025 | 112 | 0.210 |
Why?
|
| Walking | 1 | 2025 | 233 | 0.200 |
Why?
|
| Registries | 1 | 2020 | 1591 | 0.200 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2024 | 145 | 0.190 |
Why?
|
| Humans | 24 | 2025 | 132238 | 0.190 |
Why?
|
| Down Syndrome | 1 | 2025 | 232 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 342 | 0.180 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 208 | 0.180 |
Why?
|
| Exercise | 2 | 2024 | 860 | 0.180 |
Why?
|
| Echocardiography | 3 | 2024 | 1126 | 0.170 |
Why?
|
| Biopsy | 1 | 2024 | 1288 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2024 | 800 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2024 | 576 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2025 | 6568 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2022 | 204 | 0.160 |
Why?
|
| Sildenafil Citrate | 2 | 2016 | 57 | 0.150 |
Why?
|
| Infant, Premature | 2 | 2023 | 843 | 0.150 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 148 | 0.150 |
Why?
|
| Child | 11 | 2025 | 25783 | 0.150 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2007 | 6 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 150 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2017 | 36 | 0.140 |
Why?
|
| Hemophilia A | 1 | 2007 | 25 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 375 | 0.140 |
Why?
|
| Collateral Circulation | 1 | 2017 | 43 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 66 | 0.130 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2017 | 24 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2017 | 140 | 0.130 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 76 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 330 | 0.130 |
Why?
|
| Premature Birth | 1 | 2021 | 418 | 0.130 |
Why?
|
| Prognosis | 3 | 2021 | 5016 | 0.120 |
Why?
|
| Angioplasty, Balloon | 1 | 2017 | 159 | 0.120 |
Why?
|
| Growth Differentiation Factors | 1 | 2016 | 12 | 0.120 |
Why?
|
| Female | 13 | 2025 | 70780 | 0.120 |
Why?
|
| Phenotype | 1 | 2025 | 4540 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 749 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2016 | 168 | 0.110 |
Why?
|
| Hypotension | 1 | 2016 | 185 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2232 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2020 | 1050 | 0.110 |
Why?
|
| Male | 14 | 2025 | 65013 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1186 | 0.100 |
Why?
|
| Adolescent | 7 | 2025 | 20556 | 0.100 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 671 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 225 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 232 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 273 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17395 | 0.090 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 459 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2025 | 1444 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3852 | 0.080 |
Why?
|
| Mutation | 2 | 2020 | 6250 | 0.070 |
Why?
|
| Pregnancy | 1 | 2021 | 7557 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5410 | 0.060 |
Why?
|
| Survival Rate | 1 | 2020 | 2196 | 0.060 |
Why?
|
| Sample Size | 1 | 2024 | 88 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2025 | 376 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 20 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 2923 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 600 | 0.050 |
Why?
|
| Creatinine | 1 | 2024 | 413 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 51 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2017 | 609 | 0.050 |
Why?
|
| Syndrome | 1 | 2024 | 1175 | 0.050 |
Why?
|
| Heart Rate | 1 | 2024 | 584 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 821 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 504 | 0.040 |
Why?
|
| Time Factors | 2 | 2024 | 6451 | 0.040 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 31 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 71 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1841 | 0.040 |
Why?
|
| Gestational Age | 1 | 2023 | 1227 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1382 | 0.040 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2007 | 3 | 0.040 |
Why?
|
| Heart Atria | 1 | 2020 | 337 | 0.040 |
Why?
|
| Ecchymosis | 1 | 2007 | 12 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 689 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 30 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 104 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 212 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 69 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 153 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2017 | 93 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 34 | 0.030 |
Why?
|
| Polysomnography | 1 | 2017 | 155 | 0.030 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 3092 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2016 | 44 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 9966 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 162 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 144 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 487 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 3404 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 547 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 749 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 128 | 0.030 |
Why?
|
| United States | 1 | 2020 | 11669 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 76 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 89 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 699 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 548 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2007 | 517 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 283 | 0.030 |
Why?
|
| Anemia | 1 | 2007 | 350 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2017 | 336 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 31614 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 430 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2022 | 5176 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 234 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2017 | 996 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1966 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 21482 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 13027 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1612 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 10944 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 29021 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2166 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3414 | 0.020 |
Why?
|